Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fentanyl | 7 | 2021 | 35 | 3.720 |
Why?
|
| Critical Illness | 14 | 2022 | 66 | 3.180 |
Why?
|
| Analgesics, Opioid | 10 | 2022 | 113 | 2.660 |
Why?
|
| Child | 34 | 2022 | 2242 | 2.250 |
Why?
|
| Hypnotics and Sedatives | 7 | 2022 | 29 | 2.070 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2017 | 41 | 1.850 |
Why?
|
| Methadone | 4 | 2019 | 17 | 1.800 |
Why?
|
| Opioid-Related Disorders | 5 | 2013 | 41 | 1.710 |
Why?
|
| Obesity | 6 | 2019 | 669 | 1.610 |
Why?
|
| Pediatrics | 5 | 2022 | 92 | 1.540 |
Why?
|
| Hydromorphone | 2 | 2021 | 8 | 1.460 |
Why?
|
| Child, Preschool | 19 | 2021 | 1146 | 1.430 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2019 | 10 | 1.430 |
Why?
|
| Anti-Bacterial Agents | 8 | 2022 | 523 | 1.410 |
Why?
|
| Infant | 18 | 2022 | 1004 | 1.340 |
Why?
|
| Hyponatremia | 3 | 2021 | 17 | 1.330 |
Why?
|
| Ketamine | 2 | 2022 | 10 | 1.260 |
Why?
|
| Retrospective Studies | 20 | 2022 | 2546 | 1.250 |
Why?
|
| Analgesics | 5 | 2016 | 38 | 1.240 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2022 | 18 | 1.220 |
Why?
|
| Humans | 57 | 2022 | 28094 | 1.200 |
Why?
|
| Postoperative Care | 3 | 2020 | 68 | 1.190 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 607 | 1.100 |
Why?
|
| Pharmaceutical Services | 4 | 2022 | 41 | 1.060 |
Why?
|
| Pharmacists | 4 | 2022 | 72 | 1.040 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 173 | 1.020 |
Why?
|
| Pharmacy | 3 | 2022 | 35 | 0.990 |
Why?
|
| Clonidine | 3 | 2016 | 10 | 0.950 |
Why?
|
| Adolescent | 15 | 2021 | 3121 | 0.930 |
Why?
|
| Education, Pharmacy | 4 | 2021 | 115 | 0.870 |
Why?
|
| Anticoagulants | 3 | 2020 | 294 | 0.850 |
Why?
|
| Critical Care | 3 | 2022 | 49 | 0.790 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2019 | 10 | 0.730 |
Why?
|
| Female | 23 | 2020 | 15153 | 0.710 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2016 | 10 | 0.700 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 4 | 0.700 |
Why?
|
| Antitubercular Agents | 1 | 2020 | 16 | 0.690 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 3 | 0.690 |
Why?
|
| Infant, Newborn | 12 | 2022 | 885 | 0.690 |
Why?
|
| Acetylcysteine | 1 | 2020 | 24 | 0.690 |
Why?
|
| Male | 23 | 2020 | 13489 | 0.690 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 25 | 0.690 |
Why?
|
| Curriculum | 3 | 2020 | 291 | 0.680 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2019 | 14 | 0.670 |
Why?
|
| Drug Administration Schedule | 10 | 2017 | 224 | 0.670 |
Why?
|
| Warfarin | 1 | 2020 | 94 | 0.650 |
Why?
|
| Internship and Residency | 1 | 2022 | 239 | 0.640 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 18 | 0.640 |
Why?
|
| Employment | 1 | 2019 | 49 | 0.640 |
Why?
|
| Career Choice | 1 | 2019 | 53 | 0.630 |
Why?
|
| Tobramycin | 2 | 2017 | 13 | 0.600 |
Why?
|
| Lorazepam | 2 | 2017 | 7 | 0.590 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 75 | 0.570 |
Why?
|
| Status Epilepticus | 1 | 2017 | 5 | 0.550 |
Why?
|
| Anesthetics, Intravenous | 1 | 2017 | 15 | 0.550 |
Why?
|
| Anticonvulsants | 1 | 2017 | 20 | 0.550 |
Why?
|
| Ceftazidime | 3 | 2022 | 15 | 0.550 |
Why?
|
| Patient Admission | 1 | 2016 | 29 | 0.520 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 5 | 0.510 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 8 | 0.510 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 34 | 0.510 |
Why?
|
| Shock | 1 | 2016 | 17 | 0.500 |
Why?
|
| Norwood Procedures | 1 | 2016 | 13 | 0.500 |
Why?
|
| Pain Management | 2 | 2015 | 58 | 0.490 |
Why?
|
| Morphine | 1 | 2015 | 29 | 0.490 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 8 | 0.480 |
Why?
|
| Vascular Diseases | 1 | 2016 | 68 | 0.470 |
Why?
|
| Scoliosis | 1 | 2015 | 34 | 0.470 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 62 | 0.460 |
Why?
|
| Infusions, Intravenous | 6 | 2017 | 102 | 0.460 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2022 | 58 | 0.460 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 4 | 0.450 |
Why?
|
| Body Fluids | 1 | 2014 | 18 | 0.450 |
Why?
|
| Iatrogenic Disease | 2 | 2022 | 14 | 0.430 |
Why?
|
| Overweight | 2 | 2011 | 113 | 0.420 |
Why?
|
| Spinal Fusion | 1 | 2015 | 146 | 0.410 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 9 | 0.410 |
Why?
|
| Conscious Sedation | 1 | 2012 | 10 | 0.400 |
Why?
|
| Analgesia | 1 | 2012 | 13 | 0.400 |
Why?
|
| Nursing Assessment | 1 | 2012 | 27 | 0.400 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2021 | 22 | 0.400 |
Why?
|
| Immunoglobulin Fragments | 2 | 2010 | 6 | 0.390 |
Why?
|
| Antivenins | 2 | 2010 | 9 | 0.390 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2011 | 7 | 0.370 |
Why?
|
| Vancomycin | 1 | 2011 | 58 | 0.370 |
Why?
|
| Postoperative Complications | 1 | 2016 | 611 | 0.360 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 41 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 243 | 0.350 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2377 | 0.340 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 9 | 0.330 |
Why?
|
| Snake Bites | 2 | 2010 | 8 | 0.330 |
Why?
|
| Narcotic Antagonists | 1 | 2009 | 32 | 0.330 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 27 | 0.330 |
Why?
|
| Viperidae | 1 | 2008 | 3 | 0.310 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 113 | 0.300 |
Why?
|
| Time Factors | 4 | 2017 | 1591 | 0.280 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 31 | 0.280 |
Why?
|
| Adult | 6 | 2020 | 7739 | 0.280 |
Why?
|
| Internship, Nonmedical | 1 | 2007 | 3 | 0.270 |
Why?
|
| Drug Tolerance | 2 | 2021 | 37 | 0.260 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 78 | 0.260 |
Why?
|
| Serum Albumin | 1 | 2006 | 35 | 0.260 |
Why?
|
| Blood Component Transfusion | 1 | 2006 | 13 | 0.260 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 83 | 0.260 |
Why?
|
| United States | 4 | 2019 | 2146 | 0.260 |
Why?
|
| Teaching | 1 | 2007 | 83 | 0.260 |
Why?
|
| Liver Transplantation | 1 | 2006 | 56 | 0.250 |
Why?
|
| Gram-Negative Bacteria | 3 | 2022 | 62 | 0.240 |
Why?
|
| Age Factors | 2 | 2019 | 734 | 0.230 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2004 | 35 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2004 | 57 | 0.230 |
Why?
|
| Intensive Care Units | 2 | 2022 | 50 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 69 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2012 | 433 | 0.210 |
Why?
|
| Pain Measurement | 2 | 2015 | 166 | 0.210 |
Why?
|
| Acute Kidney Injury | 2 | 2017 | 74 | 0.200 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 39 | 0.200 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2022 | 148 | 0.200 |
Why?
|
| Cephalosporins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Linear Models | 2 | 2017 | 202 | 0.190 |
Why?
|
| Neuromuscular Blockade | 1 | 2022 | 8 | 0.190 |
Why?
|
| Delirium | 1 | 2022 | 13 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2017 | 887 | 0.190 |
Why?
|
| Antidotes | 1 | 2020 | 2 | 0.180 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 61 | 0.170 |
Why?
|
| Schools, Pharmacy | 1 | 2020 | 24 | 0.170 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 27 | 0.170 |
Why?
|
| Tuberculosis | 1 | 2020 | 25 | 0.170 |
Why?
|
| Fontan Procedure | 1 | 2020 | 24 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2020 | 189 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 18 | 0.170 |
Why?
|
| Furosemide | 1 | 2019 | 7 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 30 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 214 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1013 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2019 | 77 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 42 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 67 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2019 | 230 | 0.150 |
Why?
|
| Scholarly Communication | 1 | 2018 | 4 | 0.150 |
Why?
|
| Accreditation | 1 | 2018 | 35 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 78 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 35 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2019 | 399 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.140 |
Why?
|
| Hospitalization | 2 | 2017 | 198 | 0.140 |
Why?
|
| Administration, Rectal | 1 | 2017 | 5 | 0.140 |
Why?
|
| Diazepam | 1 | 2017 | 3 | 0.140 |
Why?
|
| Oklahoma | 2 | 2018 | 1007 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 33 | 0.140 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 22 | 0.140 |
Why?
|
| Midazolam | 1 | 2017 | 8 | 0.140 |
Why?
|
| Catatonia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Medical Errors | 1 | 2016 | 9 | 0.130 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 20 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 236 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 15 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 16 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2016 | 43 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 56 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 75 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 971 | 0.120 |
Why?
|
| Injections, Spinal | 1 | 2015 | 7 | 0.120 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 961 | 0.120 |
Why?
|
| Aminoglycosides | 1 | 2014 | 10 | 0.120 |
Why?
|
| Pregnancy | 1 | 2019 | 1191 | 0.120 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 4 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 207 | 0.120 |
Why?
|
| HIV Infections | 1 | 2016 | 159 | 0.110 |
Why?
|
| Amphotericin B | 1 | 2014 | 19 | 0.110 |
Why?
|
| Language Development | 1 | 2013 | 5 | 0.110 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 7 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2014 | 67 | 0.110 |
Why?
|
| Alkalosis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2013 | 6 | 0.110 |
Why?
|
| Acetazolamide | 1 | 2013 | 9 | 0.110 |
Why?
|
| Motor Skills | 1 | 2013 | 34 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2014 | 220 | 0.100 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 7 | 0.100 |
Why?
|
| Bumetanide | 1 | 2012 | 2 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2010 | 21 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2012 | 28 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 31 | 0.090 |
Why?
|
| Anxiety | 1 | 2012 | 149 | 0.090 |
Why?
|
| Disease Management | 1 | 2012 | 88 | 0.090 |
Why?
|
| United Kingdom | 1 | 2011 | 76 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 104 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 769 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 302 | 0.090 |
Why?
|
| Enoxaparin | 1 | 2011 | 37 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 2081 | 0.090 |
Why?
|
| Logistic Models | 1 | 2011 | 407 | 0.090 |
Why?
|
| Cognition | 1 | 2013 | 324 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 20 | 0.080 |
Why?
|
| Dexmedetomidine | 1 | 2009 | 2 | 0.080 |
Why?
|
| Medication Errors | 1 | 2009 | 26 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 133 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 145 | 0.080 |
Why?
|
| Kentucky | 1 | 2007 | 4 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Otitis Media | 1 | 2007 | 35 | 0.070 |
Why?
|
| Documentation | 1 | 2007 | 26 | 0.070 |
Why?
|
| APACHE | 1 | 2006 | 4 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 117 | 0.070 |
Why?
|
| Morbidity | 1 | 2006 | 58 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2006 | 34 | 0.070 |
Why?
|
| Cross Infection | 1 | 2006 | 37 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2006 | 147 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2006 | 103 | 0.060 |
Why?
|
| Length of Stay | 1 | 2006 | 229 | 0.060 |
Why?
|
| Animals | 2 | 2009 | 10415 | 0.060 |
Why?
|
| Communication | 1 | 2007 | 178 | 0.060 |
Why?
|
| Creatine | 1 | 2004 | 32 | 0.060 |
Why?
|
| Incidence | 1 | 2006 | 562 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 57 | 0.060 |
Why?
|
| Patient Selection | 1 | 2004 | 148 | 0.050 |
Why?
|
| Comorbidity | 1 | 2004 | 258 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 286 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 385 | 0.050 |
Why?
|
| Cefotaxime | 1 | 2022 | 5 | 0.050 |
Why?
|
| Monobactams | 1 | 2022 | 6 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 366 | 0.050 |
Why?
|
| Chlorothiazide | 1 | 2021 | 3 | 0.040 |
Why?
|
| Middle Aged | 2 | 2016 | 7137 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 48 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 94 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 7 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 127 | 0.040 |
Why?
|
| Faculty | 1 | 2020 | 62 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 258 | 0.040 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 22 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2022 | 337 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2020 | 83 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 26 | 0.030 |
Why?
|
| Aged | 1 | 2006 | 5400 | 0.030 |
Why?
|
| Amikacin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Gentamicins | 1 | 2014 | 15 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 43 | 0.030 |
Why?
|
| Phosphorus | 1 | 2014 | 53 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2013 | 23 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 210 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2013 | 141 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 414 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 60 | 0.020 |
Why?
|
| Crotalid Venoms | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 26 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 46 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 112 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 2732 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 46 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2007 | 271 | 0.020 |
Why?
|